Lilly's Omvoh Reaches Primary Goal in Pediatric Ulcerative Colitis Phase 3 Study

what happened

Eli Lilly said a late-stage study of Omvoh reached its primary endpoint in children with ulcerative colitis, one of the most common forms of inflammatory bowel disease. Dow Jones Newswires reports the information based on the company's statement.

According to Lilly, 81% of patients aged 6 to 17 with moderately to severely active disease achieved clinical response at week 12 of induction. Among responders, 50% reached clinical remission at week 52, which met the study's primary endpoint.

The company plans to send the results to global regulators to support a possible label expansion. Omvoh is currently approved only for adults with moderately to severely active ulcerative colitis.

why it matters

The step toward a broader label matters for the market, since a pediatric indication would widen the potential patient base for a drug already sold for adults. This is still a single study and no regulatory decision has been made, so the effect on the company's revenue remains preliminary.

market impact

Eli Lilly (LLY): a possible wider Omvoh label is a modest positive for the drug and the company.

tags

instruments